Merck, Pfizer combo treatment meets main goals of kidney cancer trial

Merck& Co said on Thursday a combination treatment of its cancer drug Keytruda and Pfizer Inc's Inlyta met the main goals of a late-stage study in patients with the most common form of kidney cancer.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news